Importantly, beyond activating ALK in neuroblastoma, F1174 mutations also emerge as an acquired resistance mutations in ALK fusion-positive tumors treated with crizotinib43 or second-generation ALK inhibitors44. This evidence concerns the gene ALK and neuroblastoma.